Harrow acquires Stanten's branded ophthalmic portfolio
Harrow states that this transaction will grant US and Canadian commercial rights to six therapeutics, including two non-prescription brands.
Six cases of occlusive retinal vasculitis linked to pegcetacoplan injection have been reported by ASRS
The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.
Eye drops could provide a more effective and comfortable therapy for retinal vein occlusion
Eye drops developed by Columbia University researchers could prove to be a more effective and comfortable therapy for retinal vein occlusion (RVO).
Researchers develop machine learning model that uses retinal scans to identify mild cognitive impairment
The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.
Astellas announced licensed use of the intravitreal retinotropic R100* vector invented by 4DMT
R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.
Non-invasive approach may predict retinopathy of prematurity earlier
Research has found a new approach that identifies high-risk infants, so that not all preemies need to undergo an invasive eye exam.
Efficacy and safety results of the ZETA-1 Phase 2 Trial in diabetic retinopathy at the 83rd Scientific Sessions of the ADA
Gonzalez shared that the ZETA-1 trial results demonstrate the potential of APX3330 to slow disease progression as well as highlight its favorable safety profile in the diabetic patient population.
Visgenx shares positive data from VGX-0111 gene therapy study in non-human primates
The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.
Study shows machine learning ability to identify diabetic retinopathy progression
The study's findings demonstrate the accuracy and feasibility of using machine learning models for identifying diabetic retinopathy (DR) progression developed using UWF images.
Eyenuk receives clearance for detecting diabetic retinopathy with the EyeArt AI system
Get caught up on the approvals and hear directly from Kaushal Solanki, PhD, Founder and CEO of Eyenuk.
Retina imaging may provide key insights to predict cerebrovascular diseases
The retina is a peripheral part of the central nervous system and shares many similarities with cerebral brain matter.
RetinalGeniX Technologies shares preview of study and goals for establishing universal biomarkers for AMD treatment
The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.
SOE 2023: Optic Neuropathy Versus Maculopathy
SOE 2023: A mixed method study of geographic atrophy
Clinical Trials at the Summit 2023: Update on visual function data from DERBY and OAKS Studies
Caroline Baumal, MD shares an update on visual function data from DERBY and OAKS Studies based on her presentation at the 2023 Clinical Trials at the Summit annual meeting, held in Park City, Utah.
Clinical Trials at the Summit 2023: Update on avacincaptad pegol for GA
Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.
Enrollment has opened for Clearside Biomedical's Phase 2b clinical trial of CLS-AX
CLS-AX is a proprietary suspension of axitinib for suprachoroidal injection being assessed for the treatment of neovascular age-related macular degeneration (wet AMD).
Prevent Blindness Day on June 1 marks the organization's 115th year
Prevent Blindness marks its 115th birthday on June 1 by declaring it Prevent Blindness Day.
Nacuity reaches target enrollment for NPI-001 tablet Phase 1/2 clinical trial for retinitis pigmentosa.
Reaching target enrollment is an important step toward Nacuity's goal to realize the potential of NPI-001 for patients affected by retinitis pigmentosa.
Coave shares positive 12-month results from Phase I/II trial of CTx-PDE6b for retinitis pigmentosa
This positive data supports Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.
Optos announces new ultra widefield color modality for increased retinal visualization
Optos announced the first ultra-widefield color rgb (red/green/blue) image. This new image modality is captured simultaneous to the optomap color rg image.
Researchers find experimental drug may prevent or slow vision loss in people with diabetes
Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.
Oxurion NV enrolls 108 patients in KALAHARI Phase 2, Part B clinical trial for diabetic macular edema
Oxurion NV has reached its enrollment target of 108 patients in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) and will likely continue to include additional participants in the trial due to high interest.
Recruitment completed for Alimera's NEW DAY study
Alimera Sciences, Inc. has completed enrollment for its NEW DAY clinical trial (NCT04469595). Participants are patients diagnosed with diabetic macular edema (DME).
Patent filed by Curative Biotechnology with international consideration
Curative Biotechnology Inc. has completed and filed a patent cooperation treaty (PCT) application with the U.S. Receiving Office.
AiViva Biopharma Inc. begins Phase 1 trial for AI007 for the treatment of wet AMD and DME
AIV007 is a broad spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation.
Oculis reveals positive top line results for OCS-01 eye drops to treat DME during Stage 1 of its Phase 3 DIAMOND trial
DIAMOND is a Phase 3, two-stage, double-masked, randomized, multi-center trial to assess the efficacy and safety of OCS-01 eye drops in DME patients. The primary objective of Stage 1 was to select the optimal dosing regimen.
ARVO 2023: YOSEMITE and RHINE trials compare faricimab to aflibercept
Roger Goldberg, MD, MBA, spoke with Ophthalmology Times® to share insights about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept.
ARVO 2023: Michael Ip shares 5 year follow-up of the original SCORE2 dataset
Michael Ip, MD, highlighted the results of the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.
ARVO 2023: Geographic atrophy progression in the Phase 3 OAKS and DERBY trials
Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.
2 Clarke Drive Cranbury, NJ 08512